Divigel Estradiol 0.1%, 0.5-1g/28 packs

Divigel Indications

Symptoms associated with estrogen deficiency, with natural or artificial menopause.
Prevention of postmenopausal osteoporosis, with a high risk of fracture, while other drugs are contraindicated for osteoporosis prevention or unusable.

Dosage & Administration

Divigel – a gel for transdermal application designed for continuous or cyclic treatment. The usual initial dose is 1 g of gel per day, which corresponds to 1 mg of estradiol. The duration of dose and selects the physician based on individual characteristics of the patient (depending on the clinical condition after 2-3 cycles dose can be corrected from 0.5 to 1.5 g of gel per day, which corresponds to 0.5-1.5 mg estradiol per day).

For patients with an intact uterus Divigel should be combined with progestogen therapy with an interval of 1 month using, for example, medroxyprogesterone acetate, norethindrone, norethindrone acetate and dydrogesterone, of at least 12-14 days.
Progestogens are not recommended for women after hysterectomy, if they had not been diagnosed with endometriosis.
Divigel should be applied to clean, dry skin.

Divigel dose is applied 1 time per day on the skin of hips, or lower body, regularly changing the place of application. Area of ​​application – 1-2 palm. Divigel should not be applied to the breasts, face, genitals, as well as skin irritation. After application of the drug is necessary to wait a few minutes until the gel is dry. Place the application should not be washed for 1 h. Avoid accidental Divigel eyes. You must wash your hands immediately after applying the gel.

Contradictions

Breast cancer (diagnosed, suspected or history).
Diagnosed or suspected estrogen-dependent malignant tumors (eg endometrial cancer).
Vaginal bleeding of unknown etiology.
Untreated endometrial hyperplasia.
Venous thromboembolic disease, presence or history (deep vein thrombosis (DVT), pulmonary embolism).
Diagnosed increased blood clotting (for example, protein C deficiency, S, or antithrombin protein).
Acute arterial thromboembolism, in the presence or history (e.g. angina, myocardial infarction).
Acute liver disease, a history or presence (before normalization of liver function laboratory parameters).
Hypersensitivity to the active substance or to any of the excipients.
Porphyry.